The purpose of this study is to assess the safety and effectiveness of an experimental device called the ProTractX3 TTS drug-coated balloon (DCB) for the treatment of benign (non-cancerous) stricture in the esophagus. A stricture is a narrowing and/or scarring of a passageway in the body which can occur in the esophagus, making it difficult to swallow food. It is common practice for doctors to use balloons or other devices to stretch and expand a stricture. The ProTractX3 DCB coating contains paclitaxel, an anti-inflammatory and anti-proliferative (anti-overgrowth) drug commonly used in the treatment of cancer. Researchers want to determine whether this drug-coated balloon dilation device can treat strictures and reduce the rate of recurrence. Participants will be randomly assigned to receive treatment with either the ProTractX3 DCB (study device) or a normal dilation. (Participants are 2 times as likely to be treated by the study device compared to the standard-of-care treatment.)
What is the full name of this clinical trial?
Paclitaxel Coated balloon for the Treatment of chronic bEnigN sTricture- Esophagus